APVO Stock — Aptevo Therapeutics Inc

Aptevo Therapeutics Inc (APVO)

Updated October 16, 2026.

APVO is a Stock. Its deepest 1-year drawdown was 94.4%.

Aptevo Therapeutics is a clinical-stage biotechnology company developing immunotherapeutic candidates for cancer treatment using its ADAPTIR and ADAPTIR-FLEX antibody platforms; its lead program is mipletamig in Phase 1b/2 trials for acute myeloid leukemia, with additional candidates in clinical and preclinical development across multiple cancer types. The company does not currently distribute to shareholders. This security appeals to investors with a high risk tolerance seeking exposure to early-stage cancer immunotherapy development.

APVO performance

Returns are updating. APVO's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 94.4%.

APVO key facts

Asset type

Stock

Asset class

Equity

Inception date

07/20/2016

Distribution frequency

None

Last close

$1.62 (as of 2026-10-16)

Market cap

$2,932,548

Average volume

30072.0

Payment date

03/27/2020

Beta

1.681

Payout ratio

0.0%

P/E ratio

0.02

Forward P/E

3.8895

EPS

$66.96

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

APVO risks and drawbacks

The deepest 1-year drawdown on record here is 94.4%.

Who may consider APVO — and who may not

It is a weaker fit for investors who need monthly cash flow (APVO does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on APVO

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions